Barclays
NRXP icon

Barclays’s NRX Pharmaceuticals NRXP Stock Holding History

Barclays’s Portfolio NRXP Stock Details NRXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.68K Buy
+900
New +$2.97K ﹤0.01% 4808

Other funds holding NRXP

BGI
B Group Inc Dallas, Texas $213M AUM 96.05% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Barclays's NRXP Position: Q2 2026 in Review

Barclays opened a new position in NRX Pharmaceuticals (NRXP) in Q2 2026: 900 shares worth $3.68K. The stake represents ﹤0.01% of the portfolio and ranks #4808 among its holdings.

47 funds tracked by Wall St. Rank hold NRXP as of Q2 2026.

  • Barclays held 900 shares of NRX Pharmaceuticals worth $3.68K as of Q2 2026.
  • NRX Pharmaceuticals was a new Barclays position in Q2 2026.
  • NRX Pharmaceuticals made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #4808 holding.
  • 47 funds tracked by Wall St. Rank held NRX Pharmaceuticals as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.